In practice, clinicians commonly begin with 0.5 g - 2 g (10 - 40 mL of 50 mg/mL solution) administered as a slow IV push or diluted infusion, adjusting per response
The EHR is designed to prompt clinicians to document medication name, dosage, route, and injection site at the point of care
Additionally, four peptides constituting KLOW have not been studied altogether in human clinical trials, therefore the side effects caused by this peptide is not well-documented and hence, research on the individual peptides and anecdotal reports from users are relied upon to know their respective side effects
In the case of injections, up to 70% of the active substance can be absorbed by the body
Before Reconstitution (Lyophilized Powder): Store vials in a refrigerator (2C to 8C or 36F to 46F)